HemoShear Therapeutics is a drug discovery company. We apply our deep understanding of complex diseases to discover new treatments for patients with rare metabolic disorders. We also partner with biopharma companies to accelerate their drug discovery and development programs in liver diseases, gout, cancer and other conditions. We are implementing a new vision for how advanced biological systems can yield new insights that improve health and quality of life for patients in need.
The biopharmaceutical industry’s drug development success is impeded by a lack of physiological models that reflect the complexity of disease. HemoShear’s proprietary REVEAL-Tx™ platform combines biological and computational models of human disease to accelerate discovery of novel targets and successful new drug treatments.
We have developed transformational physiological models of human diseases by applying principles of physiological blood flow to tissue from patients to recapitulate their disease. Our models enable valuable insights into complex disease pathways and drug responses in a more meaningful human-relevant context.
We leverage powerful computational science to extract signaling pathways from our disease models and identify novel therapeutic targets for treating diseases. We then assess our computational target hypotheses in our biological disease models.
The REVEAL-Tx™ platform enables HemoShear and our partners to gain unprecedented insight into the underlying mechanisms of disease, rapidly translate those discoveries into drug candidates, and reduce risk of failure by reliably assessing which drug candidates will be safer and more effectively treat patients.
HemoShear is discovering novel drug treatments to extend and improve the quality of life of patients with rare metabolic diseases. These genetic disorders are caused by deficiencies of certain enzymes required to metabolize proteins that leads to the rapid buildup of life-threatening toxins. Using our transformational models of these devastating diseases, our scientists are identifying and validating promising approaches to combat several inborn errors of metabolism.
501 Locust Avenue
Charlottesville, Virginia 22902